ClinicalTrials.gg
TerminatedNCT00259285Updated Jun 2, 2009Results posted

Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer

A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-02.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Trial was stopped early due to low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
195th of 224
10 · median 65
Started
2005
with 19 others
Phase 2
128 of 228
12 open now
Registered
24th of 228
by date
Lead sponsor
40 of 228
Eli Lilly and Company

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 195th largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2005, is one of 128 in phase 2, and was the 24th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of non-small-cell carcinoma of the lung
  • Patients with locally advanced disease or disease, candidates to surgery after evaluation by oncologist and thoracic surgeon
  • Tumour with possibility of curative surgery
  • At least one uni-dimensionally
  • Adequate pulmonary function to perform the planned surgical resection

Exclusion criteria

Exclusion Criteria:

  • Active infection (at the investigator's discretion)
  • Pregnancy or breast-feeding
  • Serious concomitant illness at the investigator's discretion
  • Previous diagnosis of malignant disease
  • They have received treatment during the last 30 days with a drug, other than the study drug, that has not received regulatory approval for any indication at the time of their entry in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    A

    Drug: pemetrexed · Drug: cisplatin

Interventions

  • 500 mg/m2, intravenous (IV), every 21 days x 3 cycles

    Also known as: LY231514, Alimta

  • 75 mg/m2, intravenous (IV), every 21 days x 3 cycles

06

What researchers measure

Primary outcomes

  1. Treatment Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

    Time frame: every 21 day cycle (3 cycles) and 3-4 weeks after last cycle

Secondary outcomes

  1. Pathologic Remissions After Surgery

    The status of the pathological response was evaluated on the basis of the original results of the histopathological examination of the tumour samples resected. A complete pathological response was defined as the absence of any viable tumour cell in the tumour samples obtained for histological examination.

    Time frame: surgical tumor resection (3-4 weeks after completing three 21-day cycles of therapy)

  2. Relapse-free Survival

    Results for this outcome measure were not analyzed because the trial stopped early due to low enrollment.

    Time frame: Every 21 day cycle (3 cycles) and then every 3 months for the first 2 years, every 6 months until 5 years have elapsed and annually thereafter

07

Results

Posted Jun 2, 2009
Limitations and caveats
Trial was stopped early due to low enrollment and the relapse-free survival outcome measure was not analyzed.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin
Started10
Completed10
Not completed0

Outcome measures

PrimaryTreatment Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Time frame:
every 21 day cycle (3 cycles) and 3-4 weeks after last cycle
Reported as:
Number · participants
Treatment Response
participantsPemetrexed + Cisplatin
Complete Response0
Partial Response5
Incomplete Response/Stable Disease4
Progressive Disease1
Not Evaluable0
SecondaryPathologic Remissions After Surgery

The status of the pathological response was evaluated on the basis of the original results of the histopathological examination of the tumour samples resected. A complete pathological response was defined as the absence of any viable tumour cell in the tumour samples obtained for histological examination.

Time frame:
surgical tumor resection (3-4 weeks after completing three 21-day cycles of therapy)
Reported as:
Number · participants
Pathologic Remissions After Surgery
participantsPemetrexed + Cisplatin
Complete Remission - Yes5
Complete Remission - No2
SecondaryRelapse-free Survival

Results for this outcome measure were not analyzed because the trial stopped early due to low enrollment.

Time frame:
Every 21 day cycle (3 cycles) and then every 3 months for the first 2 years, every 6 months until 5 years have elapsed and annually thereafter
Reported as:
Mean · months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 10% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin———
Most frequent serious events
Most frequent serious events
EventPemetrexed + Cisplatin
Urinary tract infectionInfections and infestations1/10
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPemetrexed + Cisplatin
NauseaGastrointestinal disorders4/10
CoughRespiratory, thoracic and mediastinal disorders3/10
VomitingGastrointestinal disorders2/10
Alanine aminotransferase increasedInvestigations2/10
Aspartate aminotransferase increasedInvestigations2/10
RashSkin and subcutaneous tissue disorders2/10
LeukocytosisBlood and lymphatic system disorders1/10
LeukopeniaBlood and lymphatic system disorders1/10
NeutrophiliaBlood and lymphatic system disorders1/10
Abdominal DistensionGastrointestinal disorders1/10

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Cisplatin
Mean61.6 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin
Female4
Male6
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin
Spain10
Eastern Cooperative Oncology Group Functional Status
Eastern Cooperative Oncology Group Functional Status(participants)Pemetrexed + Cisplatin
0 - Fully Active8
1 - Ambulatory, Restricted Strenuous Activity2
2 - Ambulatory, No Work Activities0
3 - Partially Confined to Bed, Limited Self Care0
4 - Completely Disabled0
Race/Ethnicity
Race/Ethnicity(participants)Pemetrexed + Cisplatin
Caucasian10
Body Mass Index
Body Mass Index(kilograms per square meters)Pemetrexed + Cisplatin
Mean27.1 ± 4.3
Corporal Surface (Body Surface Area)
Corporal Surface (Body Surface Area)(square meters)Pemetrexed + Cisplatin
Mean1.8 ± 0.2
Height
Height(meters)Pemetrexed + Cisplatin
Mean1.6 ± 0.1

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    A Coruña, 15006, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barakaldo, 48903, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pamplona, 31008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46014, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2005
First posted
Nov 29, 2005
Start
Nov 2005
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Jun 2, 2009
Last update
Jun 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00259285
First posted
Nov 29, 2005
Start date
Nov 2005
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Jun 2, 2009
Last update
Jun 2, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM - 5 PM Eastern time (UTC/GMT- 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion